ARCHIVES

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

This article is from The Cancer Letter archive.

Vol. 32 No. 8 | August 28, 2009

Download PDF Visit The Full Archive

Related Articles

The First BRCA1 Test Hits The Market; Are Oncologists, Patients Ready?

January 26, 1996

Clinton Budget Proposes Increase For AIDS, tuberculosis, In FY94

April 23, 1993

ACS Supports NCI’s Bypass Budget In Resolution

March 20, 1992

Other DCT Concepts Approved By Board

February 26, 1988

Lasagna Committee Urges Medicare Payment for Experimental Drugs, Care

September 29, 1989

NCI Program: Hughes Institute Official To Head Cancer Biology

July 23, 1999